Japan's plans to tackle spread of H1N1 flu Print E-mail
By Wire Reports   
Friday, 21 August 2009 02:50
Japan said this week the new H1N1 influenza virus has reached epidemic proportions in the country, but it is still lagging in vaccine production.

The new virus, which emerged in March, has been declared an international pandemic and the World Health Organization predicts a third of the global population will eventually become infected.

Companies with Certified Existing Treatments for Swine Flu

Gilead Sciences, Inc. (NASDAQ:GILD)
Roche Holding Ltd. (OTC:RHHBY)
Product: Tamiflu (oseltamivir)

GlaxoSmithKline plc (NYSE:GSK) /
Biota Holdings Ltd.(ASX:BTA)
Product: Relenza (zanamivir)

Baxter International Inc. (NYSE: BAX)
A(H1N1) vaccine using its Vero cell culture technology

Novartis AG (NYSE:NVS)
Product: Influenza A(H1N1) vaccine using Cell-based manufacturing technology

Companies with Potential Vaccines
and Treatments for Swine Flu

CEL-SCI Corporation (Amex: CVM)
Product: proprietary L.E.A.P.S. technology (Ligand Epitope Antigen Presentation System)

Biota Holdings Ltd.(ASX:BTA) /
Daiichi Sankyo
Product: CS-8958

BioCryst Pharmaceuticals,Inc. (NASDAQ:BCRX)
Product: Peramivir Intravenous

Novavax, Inc. (NASDAQ:NVAX)
Product: Swine Flu Vaccines
using Virus-like particle (VLP) technology

Inovio Biomedical Corporation (NYSE Amex:INO)
Product: SynCon™ H1N1 influenza DNA vaccines

Vical Incorporated(Public, NASDAQ:VICL)
Patented DNA delivery technology

Sinovac Biotech Ltd. (Amex: SVA)
Product: Panflu(TM)

Wyeth (NYSE: WYE)
Product: PCV13 or Prevnar 13

MedImmune / AstraZeneca PLC (NYSE:AZN)
Product: needle-free, nasal spray swine flu vaccine by using Live Attenuated Influenza Vaccine (LAIV) technology

Sanofi-Aventis SA (NYSE:SNY)
Product: Swine Flu Vaccine

Companies with Adjuvants
for Swine Flu Vaccines

Hemispherx Biopharma (AMEX:HEB)
Product: Ampligen

Antigenics, Inc. (NASDAQ:AGEN)
Product: QS-21 Stimulon

Other Technologies
Which Combat H1N1

Oculus Innovative Sciences, Inc.
Microcyn® Technology platform
Although most cases are mild to moderate, H1N1 appears to be about as deadly as the more common seasonal flu, which kills some 10,000 people a year in Japan and up to 500,000 globally.

Following are key facts about the new flu in Japan, which could become one of the first challenges for the winners of an Aug. 30 national election.

-- Japan had confirmed some 5,000 cases of the H1N1 flu as of late July, when it changed its method of tracking the outbreak. Three have died so far, with the first fatality confirmed last Saturday [ID:nT291073].

-- The government now monitors group contagion and hospitalised cases. In the week of Aug. 12-18, 86 patients were hospitalised because of the H1N1 flu, with more than 70 percent of them aged below 20.

-- Japan's National Institute of Infectious Diseases said on Friday that the new flu has reached epidemic proportions in Japan after the number of flu patients reported by about 5,000 core medical institutions rose above 1.00 per facility, which is Japan's yardstick for the start of a flu epidemic. The benchmark often rises above 1.00 with seasonal flu.

-- Japan last month confirmed its first case of a genetic mutation of the H1N1 flu virus that shows resistance to antiviral flu drug, Tamiflu, made by Switzerland's Roche AG (ROG.VX) [ID:nSP527393]. But the two main antiviral drugs, Tamiflu and GlaxoSmithkline's (GSK.L) Relenza, have helped most patients.

-- With the flu spreading at a faster rate than expected in the summer, Japan wants to delay the spread before the autumn weather sets in, worsening the situation. But it has warned that the new flu could spread more quickly once students return to school after summer holidays in September.


-- Japan wants to be ready to provide enough H1N1 flu vaccine to treat 53 million people, nearly half the country's population. But Japanese makers, which are allocating some resources away from the production of vaccines for seasonal flu, are only expected to be able to produce enough vaccine to treat 13-17 million people, far fewer than they had originally targeted. The government is considering importing vaccine to fill the gap, although some analysts said Japan should also provide vaccine to developing countries to help the poor with the disease.

-- The H1N1 flu vaccine is expected to be ready for mass vaccinations around the end of October, although the government has not yet prioritised who will be vaccinated first. A panel of experts is meeting this month to discuss this and other issues such as possible side effects of the vaccine. The government will make a final decision taking into account the panel's recommendations.

-- There are four makers that produce both seasonal and H1N1 flu vaccines for the Japanese market: Denka Seiken Co., Ltd, the Research Foundation for Microbial Diseases of Osaka University, Kaketsuken (The Chemo-Sero-Therapeutic Research Institute) and the Kitasato Institute.


-- The government has urged the public to wash their hands and gargle. It has also said that those with flu symptoms should wear masks and avoid going outside, but there are no plans to limit public gatherings.

-- The government is stockpiling antiviral drugs and planning to distribute a list of serious cases of the disease to medical institutions.

(Reporting by Yoko Nishikawa; Editing by Joseph Radford for Reuters)

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus